Zydus Lifesciences soars on reporting 9% rise in Q4 consolidated net profit
Zydus Lifesciences is currently trading at Rs. 1077.35, up by 58.40 points or 5.73% from its previous closing of Rs. 1018.95 on the BSE.
The scrip opened at Rs. 1056.15 and has touched a high and low of Rs. 1,083.00 and Rs. 1044.05 respectively. So far 125731 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1,083.00 on 20-May-2025 and a 52 week low of Rs. 835.85 on 02-Apr-2026.
Last one week high and low of the scrip stood at Rs 1,083.00 and Rs. 890.00 respectively. The current market cap of the company is Rs. 102530.21 crore.
The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 18.15% and 6.86% respectively.
Zydus Lifesciences has reported 38.80% fall in its net profit at Rs 1,722.00 crore for the fourth quarter ended March 31, 2026 as compared to Rs 2,813.70 crore for the same quarter in the previous year. The total income of the company has decreased by 29.46% at Rs 4,236.00 crore for Q4FY26 as compared to Rs 6,005.00 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 8.68% rise in its net profit at Rs 1,272.50 crore for the fourth quarter ended March 31, 2026 as compared to Rs 1,170.90 crore for the same quarter in the previous year. The total income of the company increased by 16.84% at Rs 7,721.20 crore for Q4FY26 as compared to Rs 6,608.50 crore for the corresponding quarter previous year.
For the year ended March 31, 2026, the company has reported 38.36% fall in its net profit at Rs 3,559.80 crore a
